This article is part of the Thematic Series \"Gold catalysis for organic synthesis II\".

Introduction
============

In 1967, Katagiri et al. reported the isolation of a novel antibiotic from the culture broth of the fungus *Streptomyces threomyceticus* \[[@R1]\]. The compound acts as a competitive antagonist for isoleucine in vitro and hampers the growth of several microorganisms, including the *E*. *coli*, *S*. *aureus* and *M*. *tuberculosis*. (+)-Furanomycin (**1a**, [Fig. 1](#F1){ref-type="fig"}, X = O) was identified as a non-proteinogenic amino acid bearing a characteristic 2,5-dihydrofuran ring. The correct (α*S*,2*R*,5*S*)-stereochemistry was established in 1980 by the first total synthesis by Joullié and co-workers \[[@R2]\] and the X-ray analysis of the *N*-acetyl derivative of the natural product by Shiro et al. \[[@R3]\]. (+)-Furanomycin belongs to the smallest natural antibiotics \[[@R4]\]. Therefore, the compound found considerable interest in synthetic chemistry. Until today, five total syntheses were published \[[@R2],[@R5]--[@R8]\] as well as numerous reports dedicated to derivatives and stereoisomers \[[@R9]--[@R20]\]. Examination of structure--activity relationship (SAR) revealed a loss of antibiotic activity upon shifting of the methyl group to different positions, removal of the double bond, or change of the relative configuration \[[@R14],[@R16]\]. Likewise, carbafuranomycin (**1b**) showed insufficient biological activity \[[@R17]\].

![Structure of furanomycin and its carba- and aza-anolgue.](Beilstein_J_Org_Chem-09-1936-g002){#F1}

In 2007, we reported a synthesis of furanomycin derivatives by gold-catalyzed *endo*-selective cycloisomerization of α-hydroxyallenes \[[@R19]\]. This method opens an efficient stereoselective access to chiral 2,5-dihydrofurans by axis-to-center chirality transfer ([Scheme 1](#C1){ref-type="fig"}) \[[@R21]--[@R32]\] and was applied to the total synthesis of various natural products \[[@R29]--[@R37]\]. Likewise, the corresponding gold-catalyzed cycloisomerization of various protected or unprotected α-aminoallenes affords 2,5-dihydropyrroles \[[@R29]--[@R32] [@R38]--[@R39]\]. Due to the difference in biological activity of furanomycin (**1a**) and carbafuranomycin (**1b**), we became interested in the synthesis of derivatives of the (so far unknown) azafuranomycin (**1c**). Here, we describe the first results of this study.

![Gold-catalyzed cycloisomerization of α-functionalized allenes.](Beilstein_J_Org_Chem-09-1936-g003){#C1}

Results and Discussion
======================

Since Boc-protected intermediates tend to decompose during late-stage oxidation to the carboxylic acid \[[@R19]\], we selected the Cbz-protected Garner aldehyde **2** as starting material instead of the commonly used Boc-protected analog \[[@R40]--[@R41]\]. We prepared aldehyde (*S*)/(*R*)-**2** on a multigram scale in three steps starting from commercial available (*S*)/(*R*)-serine methylester hydrochloride by treatment with Cbz-Cl \[[@R42]\], acetalization with dimethoxypropane \[[@R43]\], and ester reduction with DIBAL-H \[[@R44]\]. In our hands, this pathway was most effective as only for the reduction step Schlenk technique was necessary. Addition of lithiated *t*-butyldimethylprop-2-ynyloxysilane **3** \[[@R45]\] to (*S*)-**2** in THF at --78 °C in the presence of HMPA afforded alcohol **4** \[[@R46]--[@R50]\] in 74% yield and high *anti*-selectivity (\>95:5; [Scheme 2](#C2){ref-type="fig"}). Only traces of the *syn*-isomer were detected by TLC. Conversion of **4** into tosylate **5a** and acetate **5b** by standard conditions (*p*-TsCl/cat. DMAP in pyridine and acetic anhydride/cat. DMAP/triethylamine, respectively) proceeded in 81 and 88% yield, respectively. In contrast, treatment of alcohol **4** with diethyl chlorophosphate and *n*-BuLi or cat. DMAP in pyridine gave the phosphate **5c** in low yield. Here, direct quenching of the acetylide formed from (*S*)-**2** and lithiated **3** with diethyl chlorophosphate was more effective and afforded phosphate **5c** in 54% yield. With these propargylic electrophiles in hand, we studied the allene synthesis by copper-mediated S~N~2'-substitution \[[@R51]\] ([Table 1](#T1){ref-type="table"}, see below).

![Synthesis of propargylic electrophiles **5**.](Beilstein_J_Org_Chem-09-1936-g004){#C2}

In order to establish suitable reaction conditions, we first examined the synthesis of the butyl-substituted model substrate **6a**. Treatment of propargyl tosylate **5a** with the organocopper reagent formed in situ from *n*-BuMgCl, CuBr·SMe~2~, and LiBr \[[@R52]\] afforded allene **6a** with up to 74% yield ([Table 1](#T1){ref-type="table"}, entries 1--3). In order to achieve complete conversion, a large excess of the nucleophile is required. The yield could be raised further by using the cyanocuprate *n*-BuCu(CN)MgBr \[[@R53]--[@R55]\] or the heterocuprate *n*-BuCu(SPh)Li \[[@R56]\] ([Table 1](#T1){ref-type="table"}, entries 4 and 5). In the latter case, no formal reduction product (**6**, R^2^ = H) was observed which might have been formed by hydrolysis of a stable copper(III) intermediate \[[@R51],[@R56]\]. As expected, all S~N~2'-substitutions proceeded with excellent *anti*-stereoselectivity \[[@R51]\]. With propargyl acetate **5b** as starting material, allene **6a** was obtained in 85% yield using *n*-BuCu(CN)MgBr·2LiCl as nucleophile ([Table 1](#T1){ref-type="table"}, entry 6). In contrast, use of the heterocuprate *n*-BuCu(SPh)Li led to decomposition ([Table 1](#T1){ref-type="table"}, entry 7). Propargyl phosphate **5c** is also a suitable precursor of allene **6a** ([Table 1](#T1){ref-type="table"}, entries 8 and 9).

###### 

Copper-promoted S~N~2'-substitution of propargylic electrophiles **5** to afford allenes **6**.

  -------------------------------------------- -------- ---------------------------------------------------------- -------- ---------
  ![](Beilstein_J_Org_Chem-09-1936-i001.jpg)                                                                                
                                                                                                                            
  Entry                                        **5**    Conditions                                                 **6**    Yield/%
                                                                                                                            
  1                                            **5a**   4 equiv *n*-BuCuMgBr~2~·LiCl, THF, --60 → 0 °C, 90 min     **6a**   ---^a^
  2                                            **5a**   8 equiv *n*-BuCuMgBr~2~·LiCl, THF, --60 °C, 30 min         **6a**   55
  3                                            **5a**   10 equiv *n*-BuCuMgBr~2~·LiCl, THF, --60 → 0 °C, 90 min    **6a**   74
  4                                            **5a**   10 equiv *n*-BuCu(CN)MgBr·2LiCl, THF, --78 °C, 30 min      **6a**   83
  5                                            **5a**   4 equiv *n*-BuCu(SPh)Li, Et~2~O, --78 °C, 30 min           **6a**   80
  6                                            **5b**   10 equiv *n*-BuCu(CN)MgBr·2LiCl, THF, --78 °C → rt, 12 h   **6a**   85
  7                                            **5b**   4 equiv *n*-BuCu(SPh)Li, Et~2~O, --78 °C, 30 min           **6a**   ^---b^
  8                                            **5c**   10 equiv *n*-BuCuMgBr~2~·LiCl, THF, --78 °C, 60 min        **6a**   83
  9                                            **5c**   10 equiv *n*-BuCu(CN)MgBr·2LiCl, THF, --78 °C, 3 h         **6a**   71
  10                                           **5a**   6 equiv LiCuBr~2~, THF, reflux, 12 h                       **6b**   68
  11                                           **5a**   1.2 equiv (PhMe~2~Si)~2~CuCNLi~2~, THF, --78 °C, 30 min    **6c**   77
  12                                           **5b**   1.2 equiv (PhMe~2~Si)~2~CuCNLi~2~, THF, --78 °C, 30 min    **6c**   ^---b^
  -------------------------------------------- -------- ---------------------------------------------------------- -------- ---------

^a^Incomplete conversion. ^b^Decomposition.

After these successful model studies, we introduced substituents into the allene which can be removed at a later stage. Treatment of propargyl tosylate **5a** with lithium dibromocuprate \[[@R57]--[@R59]\] or the silylcuprate (PhMe~2~Si)~2~CuCNLi~2~ \[[@R60]--[@R61]\] afforded the allenes **6b** and **6c** with 68 and 77% yield, respectively ([Table 1](#T1){ref-type="table"}, entries 10 and 11). Also these S~N~2'-substitution took place with complete *anti*-stereoselectivity. In contrast, decomposition occurred when propargyl acetate **5b** was treated with the silyl cuprate ([Table 1](#T1){ref-type="table"}, entry 12).

The next steps towards the substrates of the gold-catalyzed cycloisomerization proceeded uneventfully ([Scheme 3](#C3){ref-type="fig"}). Desilylation of allenes **6a** and **6b** with tetrabutylammonium fluoride trihydrate afforded the α-hydroxyallenes **7a**/**b** in high yield, and these were converted into the aminoallenes **8a**/**b** under standard Mitsunobu conditions (DEAD, PPh~3~, phthalimide; then hydrazine monohydrate) \[[@R38]--[@R39] [@R62]\]. Unfortunately, fluoride-mediated desilylation of allene **6c** caused complete epimerization of the allenic chirality axis. Therefore, the silylallene was not used in further studies.

![Synthesis of α-hydroxyallenes **7** and α-aminoallenes **8**.](Beilstein_J_Org_Chem-09-1936-g005){#C3}

The results of the gold-catalyzed cycloisomerization of the allenes **7** and **8** to the five-membered heterocycles **9**/**10** are summarized in [Table 2](#T2){ref-type="table"}. Treatment of the α-hydroxyallene **7a** with 1 mol % AuCl~3~ in THF \[[@R21]--[@R23]\] afforded the desired 2,5-dihydrofuran **9a** with 84% yield ([Table 2](#T2){ref-type="table"}, entry 1). The temperature was decreased to 5 °C to avoid acetal cleavage by the Lewis-acidic gold catalyst \[[@R19]\]. For the corresponding cyclization of the bromoallene **7b**, the temperature had to be raised to 50°C in order to achieve complete conversion ([Table 2](#T2){ref-type="table"}, entry 2). Only traces of the acetal cleavage product were detected by TLC. However, the cycloisomerization was accompanied by partial epimerization of the allene, so that dihydrofuran **9b** was isolated as a 4:1-mixture of diastereomers.

###### 

Gold-catalyzed cycloisomerization of allenes **7** and **8**.

  -------------------------------------------- ------------- ------------------------------------------------------------------------------- -------------- ---------
  ![](Beilstein_J_Org_Chem-09-1936-i002.jpg)                                                                                                                
                                                                                                                                                            
  Entry                                        **7**/**8**   Conditions                                                                      **9**/**10**   Yield/%
                                                                                                                                                            
  1                                            **7a**        1 mol % AuCl~3~,THF, 5 °C, 12 h                                                 **9a**         84
  2                                            **7b**        2 mol % AuCl~3~, THF, 50 °C, 5 h                                                **9b**         77^a^
  3                                            **8a**        10 mol % AuCl, 10 mol % imidazole, DCE, 80 °C, 12 h                             **10a**        66^b^
  4                                            **8a**        10 mol % AuCl, 10 mol % imidazole, toluene, 80 °C, 12 h                         **10a**        78
  5                                            **8b**        7 mol % Ph~3~PAuCl, 7 mol % AgBF~4~, 7 mol % imidazole, toluene, 100 °C, 12 h   **10b**        47^c^
  -------------------------------------------- ------------- ------------------------------------------------------------------------------- -------------- ---------

^a^dr = 4:1. ^b^The *N*-chloroethylated dihydropyrrole was formed as side product (29% yield). ^c^Yield of the twofold protected dihydropyrrole **11b** obtained by treatment of **10b** with CbzCl and DMAP; 2'-*epi*-**11b** was obtained as minor product (4% yield).

As expected, the cycloisomerization of allenes **8** bearing an unprotected amino group is much slower \[[@R38]--[@R39]\] and requires rather forcing conditions. For a complete conversion of α-aminoallene **8a**, 10 mol % of AuCl \[[@R38]--[@R39]\], 10 mol % of imidazole as stabilizing ligand and an elevated temperature (80 °C) are necessary. With dichloroethane as solvent, dihydropyrrole **10a** was obtained in 66% yield ([Table 2](#T2){ref-type="table"}, entry 3); however, this was accompanied by 29% of the corresponding *N*-chloroethylated product. This undesired side product could be avoided by using toluene as the solvent ([Table 2](#T2){ref-type="table"}, entry 4). Application of these conditions to the brominated α-aminoallene **8b** gave incomplete conversion. Full conversion was achieved with 7 mol % each of Ph~3~PAuCl, AgBF~4~ and imidazole in toluene at 100 °C ([Table 2](#T2){ref-type="table"}, entry 5). The dihydropyrrole **10b** thus formed could not purified completely even after repeated column chromatography. Therefore, the crude product was treated with CbzCl and DMAP \[[@R63]\] to give the twofold protected dihydropyrrole **11b** (formula not shown) with 47% yield over two steps. Additionally, we isolated the epimeric compound 2'-*epi*-**11b** in 4% yield, indicating a minimal epimerization of bromoallene **8b** during the gold-catalyzed cyclization.

The synthesis of azafuranomycin analogs was continued with the twofold Cbz-protected heterocycle **11a** which was obtained with 79% yield by treatment of **10a** with CbzCl and DMAP \[[@R63]\] ([Scheme 4](#C4){ref-type="fig"}). This protection step was carried out in order to avoid dehydrogenation or chlorination of the secondary amine in the subsequent oxidation steps \[[@R64]--[@R65]\]. Acetal cleavage under mild protic conditions furnished the hydroxycarbamate, which underwent two-step oxidation with Dess--Martin periodinane \[[@R66]--[@R67]\] and sodium chlorite in buffered solution \[[@R68]\] in the presence of resorcine \[[@R19]\]. The carboxylic acid **12a** was isolated in 65% yield. Finally, the protecting groups were removed with trifluoracetic acid in the presence of thioanisole \[[@R69]\] to afford the azafuranomycin analog **13a** with 31% yield. Later, we found that a higher excess of thioanisole, which captures benzylic cations in the deprotection step, affords higher yields of the amino acid ([Scheme 5](#C5){ref-type="fig"}).

![Synthesis of azafuranomycin analog **13a**.](Beilstein_J_Org_Chem-09-1936-g006){#C4}

![Synthesis of (α*S*,2*R*)-(2,5-dihydro-1*H*-pyrrol-2-yl)glycine (**22**).](Beilstein_J_Org_Chem-09-1936-g007){#C5}

After successful conclusion of the model studies, the synthesis of (α*S*,2*R*)-(2,5-dihydro-1*H*-pyrrol-2-yl)glycine (**22**, normethylazafuranomycin) was carried out ([Scheme 5](#C5){ref-type="fig"}). The aldehyde (*R*)-**2**, which was prepared from D-serine \[[@R42]--[@R44]\], underwent chelation-controlled nucleophilic addition of metallated alkyne **3** \[[@R45]\] to give the propargyl alcohol **14** in 84% yield and a *syn*-diastereoselectivity of \>95:5 \[[@R7],[@R46]--[@R47]\]. After tosylation of **14** (85% yield), synthesis of the bromoallene **15** with lithium dibromocuprate resulted in an unexpected epimerization of the allene moiety to afford an inseparable 2:1-mixture of diastereomers in 66% yield. Addition of stabilizing ligands ((*n*-Bu)~3~P or (*n*-BuO)~3~P) did not affect this loss of stereoselectivity. Fortunately, the correct stereoisomer was enriched at the stage of the dihydropyrrole **18** due to several purification steps.

Desilylation of **15** with tetrabutylammonium fluoride trihydrate (94% yield) and conversion of **16** into the α-aminoallene **17** under Mitsunobu conditions (45% yield) \[[@R38]--[@R39] [@R62]\] set the stage for the gold-catalyzed cycloisomerization. This was carried out with 10 mol % each of AuCl and imidazole in toluene at 100 °C to give the desired dihydropyrrole **18** in ca. 67% yield. Similar to the diastereomer **10b**, compound **18** could not be purified in a sufficient manner even after repeated column chromatography. Treatment of **18** with CbzCl/DMAP \[[@R63]\] gave the fully protected heterocycle **19** in 42% yield over two steps from **17**. The spectroscopic data are identical with those of 2'-*epi*-**11b**, except for the sign of the optical rotation {**19**: \[α\]^19^ ~D~ +37.9 (*c* 1.27, CHCl~3~); 2'-*epi*-**11b**: \[α\]^20^ ~D~ --47.0 (*c* 0.10, CHCl~3~)}.

For the debromination of dihydropyrrole **19**, we first tested radical conditions ((*n*-Bu)~3~SnH/AIBN), but these led to complete decomposition. This is surprising since carbamates are known to be stable under radical conditions \[[@R70]\]. Indeed, treatment of diastereomer **11b** with (*n*-Bu)~3~SnH/AIBN afforded the desired dehalogenated dihydropyrrole with 66% yield (formula not shown). For the conversion of **19** to **20**, we applied a bromine--lithium exchange with 2 equivalents of *t*-BuLi in diethyl ether at --90 °C \[[@R71]\], followed by hydrolysis. Even though oxazolidines are known to be sensitive towards organolithium compounds \[[@R19],[@R72]--[@R74]\], dehalogenated dihydropyrrole **20** was obtained in 60% yield, together with 22% of reisolated **19**. The remaining steps towards azafuranomycin analog **22** followed those established for **13a**: acetal cleavage (71% yield), two-step oxidation which afforded protected amino acid **21** with 72% yield \[[@R19],[@R66]--[@R68]\], and final deprotection according to the procedure of Kiso et al. (50 equiv thioanisole and 270 equiv TFA per Cbz-group) \[[@R69]\] gave the target molecule **22** with 66% yield after purification by ion exchange chromatography (DOWEX 50W X8).

Conclusion
==========

We have developed the first synthesis of the azafuranomycin analog (α*S*, 2*R*)-(2,5-dihydro-1*H*-pyrrol-2-yl)glycine (**22**) in 13 linear steps with an overall yield of 2.4% starting from the Cbz-protected Garner aldehyde (*R*)-**2**. The key step is the gold-catalyzed cycloisomerization of α-aminoallene **17** to dihydropyrrole **18**. The sequence was first tested in model studies which afforded butyl-substituted azafuranomycin derivative **13a** in 12 linear step with an overall yield of 2.9% starting from (*S*)-**2**.
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